TNF-a (about 60 pg/ml). Interestingly, NKG2D þ CD8 þ T cells did not respond with a secretion of TNF-a in the presence of the immuno-ligand ULB-scFv CD33. Moreover, there is also no killing of AML cells by T cells in the presence of just the immuno-ligand ( Figure 1E, e4) . Furthermore, the killing capability of T cells in the presence of both bispecific anti-CD33 compounds is not significantly enhanced ( Figure 1E, e4) . These results which are in good agreement with previously published data 6, 7 suggest that the signaling mediated by NKG2D can corroborate the signaling through the CD3 complex of the T cell receptor, but is not sufficient for killing of the target cell.
Consequently, the killing of AML cells in the presence of the immuno-ligand ULB-scFv CD33 observed by PBMCs was mainly mediated by NK cells.
Stimulated by these data, we wanted to know whether or not a simultaneous redirection of T-and NK cells in the presence of both bispecific anti-CD33 antibody constructs is superior over redirecting of a single group of effector cells ( Figure 1F, f1) . As shown in Figure 1F (f2, f3), a simultaneous redirection of these effector cells clearly leads to an increased release of pro-inflammatory cytokines including IFN-g ( Figure 1F , f2) and TNF-a ( Figure 1F, f3) . Moreover, the combined retargeting improves the killing efficiency of the retargeted effector cells ( Figure 1F , f4). To show this beneficial effect, the tumor cell lysis was performed at suboptimal concentrations of both compounds. Under these conditions retargeting of T cells (including T cells positive for NK cell receptors) resulted in a maximal lysis of about 60% of tumor cells (effector to target cell ratio of 20:1) and retargeting of NK cells (including T cells positive for NK cell receptors) resulted in a maximal lysis of about 50%, whereas a simultaneous retargeting of these immune effector cells increased the lysis of the target cells to almost 100% ( Figure 1F, f4) .
In summary, we here described two novel bispecific anti-CD33 antibody constructs for engaging CD33-positive AML blasts by either CD3 þ and/or NKG2D þ effector cells. NKG2D þ CD8 þ T cells redirected by the CD3 complex were costimulated by the NKG2D receptor pathway. Moreover, a simultaneous retargeting of T-and NK cells is superior over the retargeting of a single immune effector cell. Thus, both anti-CD33 antibody derivatives are promising candidates for further development toward clinical testing either alone or in combination.
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Drs S Stamova and M Bachmann have applied for patents related to the novel anti-CD33 abs and the novel linker module. Myeloproliferative neoplasms (MPN) have been associated with several mutations including those that involve JAK, MPL, TET2, IDH, CBL, IKZF1, EZH2 and LNK. None of these mutations is currently considered a disease-initiating event and previous studies have suggested the absence of mutual exclusivity amongst mutations; clonal hierarchy could not be predicted when two or more of these mutations co-exist in the same patient. 1 The recent discovery of LNK mutations in JAK2V617F-negative MPN suggested an alternative mechanism of JAK-STAT (Janus kinase/signal transducers and activators of transcription) activation and clonal erythrocytosis. 2, 3 However, subsequent studies showed that JAK2 and LNK mutations are not necessarily mutually exclusive and the pathogenetic contribution of LNK mutations, in the presence of JAK2V617F, remains unclear. 4 We recently detected two distinct LNK mutations in each of two patients with primary myelofibrosis. One of the patients had two LNK mutations (LNK 955_delA and LNK 685-691_delGGCC CCG) and also harbored IDH2R140Q and JAK2V617F, in both chronic-and blast-phase samples. This patient had a normal karyotype. In a Mayo Clinic Institutional Review Board approved study, we conducted single colony studies to determine the clonal sub-structure in this patient and subcloning experiments to ascertain whether the two LNK mutations occurred on the same or different LNK alleles.
Single colonies were grown from peripheral blood mononuclear cells collected during chronic phase, and erythroid colonies were genotyped for each of the aforementioned mutations. The results identified LNK 955_delA as the earliest event, IDHR140Q as the second, LNK 685-691_delGGCCCCG the third and JAK2V617F as the last, in the order of clonal evolution (Figure 1) . It was also evident that clones with multiple mutations were over-represented, suggesting a growth advantage over clones with less complex mutation profile (Figure 1) . Reverse transcriptase-PCR products from enriched CD34 þ cells collected during chronic phase were subsequently sub-cloned, using primers encompassing the region of LNK involved with the two mutations, and sequenced: 6 of 10 sub-clones carried only LNK 685-691_del GGCCCCG and 4 only LNK 955_delA. This confirmed that both LNK alleles were vulnerable to functionally relevant mutations.
Taken together, the results of this study underscore the complexity of clonal structure and composition in MPN. Specifically, LNK mutations were shown to be acquired either early or late during the course of clonal evolution, and were not mutually exclusive of other MPN-relevant mutations. Furthermore, LNK mutations were for the first time demonstrated to involve both LNK alleles, suggesting a selective advantage for lower LNK protein levels than is seen in the simple heterozygous mutated state; in this case, two different mutations appear to have involved each LNK allele in an independent and sequential fashion. Previous studies have shown the occurrence of double JAK2 mutations in the form of both independent clones, 5 and the same clone with the two mutations in cis configuration. 6 The double LNK mutation in our patient were in trans and the presence of single colonies with both homozygous LNK 685-691_del GGCCCCG and heterozygous LNK 955_delA further illustrate the extent of genomic instability associated with clonal evolution; the underlying mechanism for loss-of-heterozygosity involving only one of the two LNK mutations could not be ascertained. 
